Search the Newsreel

Telomir Pharmaceuticals Inc (TELO) Financial Health: Profitability & Balance Sheet Analysis

This article analyzes the financial health of Telomir Pharmaceuticals Inc (TELO), which has a current financial score of 6.88 out of 10, ranking 131st out of 155 in the Pharmaceuticals industry. The analysis indicates robust financial status but low operating efficiency. Key financial metrics …

Telos: Substantial Pipeline Opportunities And Likely Guidance Raise

Frontier tech research, news & data

The article provides a detailed snapshot of TELOS CORP's (TLS) return ratios, including return on equity, assets, and invested capital, for both annual fiscal years and quarterly periods. It highlights that the company's return on equity in FY2025 was -38.1%, and on a trailing-twelve-month …

Review of 50+ CBD studies finds drug interactions in retail products

A review of over 50 studies on low-dose cannabidiol (CBD) products, published in the British Journal of Clinical Pharmacology and led by an Artelo scientist, found that common over-the-counter CBD doses (≤2.5 mg/kg or ≤175 mg/day) yielded little to no therapeutic effect and had …

New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition

A new peer-reviewed article in the British Journal of Clinical Pharmacology, co-authored by Artelo Biosciences, reveals that over 50 studies found low-dose non-prescription CBD products lack therapeutic efficacy due to insufficient exposure. Artelo's optimized CBD composition, ART12.11, aims to address this challenge by improving …

Artelo Biosciences (NASDAQ: ARTL) awards 136-share option to director

Artelo Biosciences (NASDAQ: ARTL) director Steven Kelly was granted stock options for 136 shares at an exercise price of $1.15 per share. The options will vest 100% on the earlier of one year from July 17, 2026, or the day before the next annual …

Artelo Biosciences (ARTL) grants small stock option award to director

Artelo Biosciences (ARTL) has granted a stock option covering 136 shares to director Connie Matsui, with an exercise price of $1.15 per share and an expiration date of July 17, 2036. The options will vest 100% on the earlier of one year from the …

12 Health Care Stocks Moving In Tuesday's Intraday Session

This article lists 12 health care stocks that experienced significant price movements during Tuesday's intraday trading session. It highlights several companies as top gainers, including China Pharma Holdings and Wellgistics Health, and also identifies key losers such as Zhengye Biotechnology and Lisata Therapeutics, providing …

Artelo Biosciences grants options to director | ARTL Insider Trading

Artelo Biosciences director Robert Martin received a grant of 136 stock options with an exercise price of $1.15 per share, expiring on July 17, 2036. The options will vest 100% on the earlier of one year from July 17, 2026, or the day before …

Artelo Biosciences (ARTL) awards stock options to director Douglas Blayney

Artelo Biosciences (ARTL) has granted its director, Douglas Blayney, stock options for 136 shares of common stock. The options have an exercise price of $1.15 per share and will expire on July 17, 2036. The shares are set to vest 100% on the earlier …

Artelo Biosciences (ARTL) Proxy filing Summary

Artelo Biosciences (ARTL) has released a proxy filing summary detailing voting matters for its upcoming annual meeting. Shareholders are asked to elect three directors—Gregory R. Reyes, Tamara A. Favorito, and Gregory D. Gorgas—and to approve an amendment to increase authorized common stock from 166,666,667 …

Telomir Pharmaceuticals (NASDAQ:TELO) Stock Price Down 17.2% - Here's Why

Artelo Biosciences (NASDAQ: ARTL) details 2026 director and shareholder vote tallies

Artelo Biosciences, Inc. (NASDAQ: ARTL) reported the results of its Annual Meeting of Stockholders held on July 17, 2026. Stockholders voted on the re-election of three Class III directors and approved two other proposals, including an increase in authorized common stock and a share …

Artelo Biosciences (ARTL) AGM 2026 Summary

Artelo Biosciences (ARTL) held its 2026 Annual General Meeting, where shareholders considered several key proposals. These included the re-election of three Class III directors, an amendment to increase the authorized common stock from 166,666,667 to 500 million, and approval for issuing over 20% of …

ARTL: All proposals, including director elections and share increases, were approved

Artelo Biosciences, Inc. (ARTL) shareholders approved all proposals during their 2026 AGM, including director elections, an increase in authorized shares, and a major equity issuance. No shareholder questions were raised during the Q&A session. This information is based on the company's AGM 2026 Audio …

Artelo presents preclinical data on osteoarthritis pain drug

Artelo Biosciences announced preclinical study results for ART26.12, its osteoarthritis pain drug, showing it reduced pain behaviors in studies and had comparable efficacy to naproxen with fewer side effects. The company plans to start a clinical study in Q4 to evaluate its safety and …

Artelo Biosciences, Inc. Announces Results from Nonclinical Osteoarthritis Study Supporting ART26.12 as Potential First-In-Class New Therapy for Chronic Pain Conditions

Artelo Biosciences announced positive nonclinical study results for ART26.12, its FABP5 inhibitor, showing its potential as a first-in-class treatment for osteoarthritis pain. The drug demonstrated efficacy comparable to naproxen in reducing pain, while significantly minimizing gastrointestinal tissue damage, suggesting a safer profile than traditional …

Artelo Biosciences Issues Reminder to Shareholders to Vote in Advance of Annual Meeting on July 17, 2026

Artelo Biosciences is reminding its shareholders to vote their shares before its Annual Meeting on July 17, 2026. The company emphasizes that submitting a proxy is crucial for establishing the necessary quorum, regardless of how shareholders choose to vote. This participation ensures the company …

Here’s What Driving Telos Corporation (TLS) Higher

Antelopus Selan Energy promoter declares no encumbrance in FY26

Investors Shouldn't Be Too Comfortable With Antelopus Selan Energy's (NSE:ANTELOPUS) Earnings

Telos Corporation (TLS) Q1 Earnings and Revenues Top Estimates

ANTELOPUS Standalone March 2026 Net Sales at Rs 102.01 crore, up 65.28% Y-o-Y

Antelopus Selan Energy standalone net profit rises 157.65% in the March 2026 quarter

Telos (NASDAQ: TLS) CEO on medical leave as Q1 exceeds guidance

Inside Telos Corp (TLS)’s Plan for Growth and Shareholder Returns

Antelopus Selan Energy Limited Submits SEBI Compliance Certificate for Q4FY26

Market Cool On Telos Corporation's (NASDAQ:TLS) Revenues Pushing Shares 25% Lower

Telos: Rapid Growth Surge And Still Under-Recognized In The Market (NASDAQ:TLS)

Antelopus Selan Energy Reports Strong Q3FY26 Performance with 35% Production Growth

Antelopus Selan Energy Limited Responds to BSE Clarification on Share Price Movement

Antelopus Selan Energy Clarifies Recent Share Price Fluctuations

Antelopus Selan Energy Ltd. Share Price Live Today

Antelopus Selan Energy Ltd. Share Price Today | Antelopus Selan Energy Live NSE/BSE